#1 Clinical Trials Search in Europe

Tofacitinib

This article explores the use of tofacitinib, a Janus kinase (JAK) inhibitor, in various clinical trials. Tofacitinib has been studied for its potential in treating conditions such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and dry eye disease. The trials aim to evaluate the drug’s safety, efficacy, and optimal dosing across different formulations and patient populations.

Table of Contents

What is Tofacitinib?

Tofacitinib is a medication used to treat various inflammatory conditions. It belongs to a class of drugs called Janus kinase (JAK) inhibitors. Tofacitinib is also known by the brand name Xeljanz[1]. This medication works by reducing inflammation in the body, which helps alleviate symptoms associated with certain autoimmune disorders.

How Does Tofacitinib Work?

Tofacitinib works by blocking specific enzymes in your body called Janus kinases. These enzymes play a crucial role in the inflammatory process. By inhibiting these enzymes, tofacitinib helps reduce inflammation and modulate the immune system’s response. This action can help control symptoms and slow down the progression of certain inflammatory diseases[2].

Conditions Treated with Tofacitinib

Tofacitinib is used to treat several inflammatory conditions, including:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting the joints[2]
  • Psoriatic Arthritis: A form of arthritis that affects some people with psoriasis[3]
  • Ulcerative Colitis (UC): A chronic inflammatory bowel disease affecting the large intestine[4]
  • Juvenile Idiopathic Arthritis (JIA): A type of arthritis that affects children[5]
  • Ankylosing Spondylitis (AS): An inflammatory disease that can cause some of the vertebrae in your spine to fuse[1]

How is Tofacitinib Administered?

Tofacitinib is typically taken orally in the form of tablets or an oral solution. The dosage and frequency depend on the condition being treated, the patient’s age, and body weight. For example:

  • For adults with rheumatoid arthritis, the usual dose is 5 mg twice daily[2]
  • For children with juvenile idiopathic arthritis, the dosage is based on body weight, ranging from 2 mg to 5 mg twice daily[6]
  • An oral solution (1 mg/mL) is available for patients who have difficulty swallowing tablets or for children weighing less than 40 kg[7]

Efficacy of Tofacitinib

Clinical trials have shown tofacitinib to be effective in treating various inflammatory conditions:

  • Rheumatoid Arthritis: Studies have demonstrated significant improvements in joint pain, swelling, and overall disease activity in patients with RA[8]
  • Psoriatic Arthritis: Tofacitinib has shown effectiveness in reducing joint symptoms and improving skin manifestations in patients with psoriatic arthritis[3]
  • Ulcerative Colitis: The medication has been found to induce and maintain remission in patients with moderate to severe ulcerative colitis[4]
  • Juvenile Idiopathic Arthritis: Tofacitinib has demonstrated efficacy in reducing disease activity and improving physical function in children with JIA[6]

Potential Side Effects and Safety Considerations

Like all medications, tofacitinib can cause side effects. Some common side effects include:

  • Upper respiratory tract infections
  • Headache
  • Diarrhea
  • Nasopharyngitis (inflammation of the nasal passages and throat)

More serious side effects, although less common, may include:

  • Increased risk of serious infections
  • Changes in blood cell counts
  • Elevated liver enzymes
  • Increased risk of certain cancers
  • Gastrointestinal perforations (holes in the stomach or intestines)

It’s important to discuss the potential risks and benefits of tofacitinib with your healthcare provider. Regular monitoring through blood tests and check-ups is typically required while taking this medication[8].

Ongoing Research and Future Applications

Researchers continue to study tofacitinib for its potential use in other conditions. For example, a recent study investigated its use in hospitalized patients with COVID-19 pneumonia[9]. While the results of this study are not included in the provided information, it demonstrates the ongoing interest in exploring new applications for this medication.

As research progresses, we may see tofacitinib being used to treat additional inflammatory or autoimmune conditions in the future. Always consult with your healthcare provider for the most up-to-date information on tofacitinib and its potential uses.

Aspect Details
Drug Name Tofacitinib (also known as CP-690,550, Xeljanz)
Drug Class Janus kinase (JAK) inhibitor
Conditions Studied Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis, Dry eye disease, Dermatomyositis
Formulations Oral tablets (immediate and modified release), Topical gel, Oral solution
Dosages Varying by study: 5mg BID, 10mg BID, 11mg QD, weight-based dosing for children
Primary Outcomes ACR20 response, Changes in DAS28 scores, HAQ-DI improvements
Secondary Outcomes ACR50/70 responses, PASI75, Quality of life measures (SF-36, EQ-5D), Fatigue scores
Safety Monitoring Adverse events, Laboratory abnormalities, Infections
Study Durations Ranging from 12 weeks to long-term extension studies
Special Populations Adults, Children with JIA, Treatment-refractory patients

FAQ

  • What is tofacitinib and how does it work? Tofacitinib is a Janus kinase (JAK) inhibitor that works by blocking certain enzymes in the body that are involved in the immune response. It helps reduce inflammation and symptoms in various autoimmune conditions.
  • What conditions are being studied with tofacitinib in these clinical trials? The clinical trials are investigating tofacitinib for conditions including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, dry eye disease, and dermatomyositis.
  • How is tofacitinib administered in these studies? Tofacitinib is administered in various forms across the studies, including oral tablets (immediate release and modified release), topical gel, and oral solution for children. Dosages and frequencies vary depending on the specific trial and condition being studied.
  • What are some of the main outcomes being measured in these trials? The trials are measuring outcomes such as changes in disease activity scores, improvements in joint function, reductions in pain and fatigue, quality of life measures, and safety assessments including adverse events and laboratory abnormalities.
  • Are there any notable side effects or safety concerns with tofacitinib? While specific safety data varies by trial, common areas of monitoring include changes in laboratory values (such as blood cell counts and liver enzymes), infections, and other adverse events. Long-term safety is an important aspect being evaluated in these studies.

Ongoing Clinical Trials on Tofacitinib

  • Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Tofacitinib and Drug Combination on Blood Clotting in Patients with Ulcerative Colitis

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Immune Response to Recombinant Zoster Vaccine in Rheumatic Disease Patients Using Baricitinib, Tofacitinib, or Methotrexate

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Morning vs. Evening Dosing of Tofacitinib for Patients with Rheumatoid or Psoriatic Arthritis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Infliximab, Tofacitinib, and Vedolizumab in Patients with Ulcerative Colitis Resistant to Initial Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Poland

  • Study on Reducing JAK Inhibitor Doses in Patients with Low Disease Activity in Rheumatoid Arthritis Using Tofacitinib and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Italy Lithuania Portugal +1

  • Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Czechia France Germany The Netherlands Spain

Glossary

  • Janus kinase (JAK) inhibitor: A type of medication that works by blocking specific enzymes involved in the immune response and inflammation process.
  • Rheumatoid arthritis: A chronic inflammatory disorder that primarily affects the small joints of the hands and feet.
  • Psoriatic arthritis: A form of arthritis that affects some people with psoriasis, causing joint pain, stiffness, and swelling.
  • Juvenile idiopathic arthritis: A type of arthritis that affects children, causing joint pain, swelling, and stiffness.
  • Dermatomyositis: A rare inflammatory disease characterized by muscle weakness and skin rash.
  • ACR20/50/70: Measures of improvement in rheumatoid arthritis symptoms, indicating 20%, 50%, or 70% improvement respectively.
  • DAS28: Disease Activity Score in 28 Joints, a measure of disease activity in rheumatoid arthritis.
  • HAQ-DI: Health Assessment Questionnaire – Disability Index, a measure of functional ability in arthritis patients.
  • PASI75: Psoriasis Area and Severity Index 75, indicating a 75% improvement in psoriasis symptoms.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Modified release: A drug formulation designed to release the active ingredient over an extended period or at a specific time.
  • Placebo: An inactive substance or treatment used as a control in clinical trials to test the effectiveness of an active medication or treatment.

References

  1. https://clinicaltrials.gov/study/NCT03502616
  2. https://clinicaltrials.gov/study/NCT04413617
  3. https://clinicaltrials.gov/study/NCT03486457
  4. https://clinicaltrials.gov/study/NCT06625450
  5. https://clinicaltrials.gov/study/NCT01500551
  6. https://clinicaltrials.gov/study/NCT02592434
  7. https://clinicaltrials.gov/study/NCT04111614
  8. https://clinicaltrials.gov/study/NCT03387423
  9. https://clinicaltrials.gov/study/NCT04412252